ReviewMaturitas2010
Male breast cancer: an update in diagnosis, treatment and molecular profiling.
Review in Maturitas, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Male breast cancer: a report of 25 cases.The Pan African medical journal · 2020Article
- Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.Oncotarget · 2016Article
- Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.Cancer research and treatment · 2016Article
- Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit.International journal of surgery case reports · 2016Article
- Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review.European journal of medical research · 2015Review
- Breast cancer risk factors.Przeglad menopauzalny = Menopause review · 2015Review
- Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer.Hereditary cancer in clinical practice · 2015Article
- Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.Therapeutic advances in drug safety · 2014Review
- Clinicopathologic characteristics and survival of male breast cancer.International journal of clinical oncology · 2014Article
- Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series.British journal of cancer · 2013Article
- Invasive ductal breast carcinoma underneath a lipoma in a male patient.The Journal of clinical and aesthetic dermatology · 2012Article
- Breast cancer medications and vision: effects of treatments for early-stage disease.Current eye research · 2011Review
- Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients.Breast cancer research and treatment · 2011Article
- Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.Annals of surgical oncology · 2011Article
- Male breast cancer: a report of 127 cases at a Moroccan institution.BMC research notes · 2011Article
- Strictly defined familial male breast cancer.Familial cancer · 2011Article
- Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.Breast disease · 2011Article
- [Male breast cancer: a challenge for urologists].Der Urologe. Ausg. A · 2010Review
- Male Breast Cancer: A Rare Entity.JNMA; journal of the Nepal Medical AssociationArticle
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Significant advances have been made in the diagnosis and treatment of female breast cancer, resulting in a decline in incidence and a global improvement in clinical outcome. The statistics for male breast cancer (MBC) stand in sharp contrast-over the past several decades, there has been a steady rise in the incidence of this disease, and clinical outcome has improved at a much slower pace. In the current review, the clinicopathologic features of MBC are described in detail. An emphasis is placed on molecular profiling of MBC, which may identify candidate biomarkers and putative targets for pharmacologic intervention. The current role of cytotoxic chemotherapy and endocrine therapy (including tamoxifen, aromatase inhibitors and GnRH analogues) is defined in the context of currently available studies. Furthermore, the potential role of targeted agents, including HER2-directed therapies, PARP inhibitors, and angiogenesis inhibitors, is delineated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.